Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN. The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”
Celularity’s abstract explores the application of various decellularized placental biomaterials, including connective tissue matrix (CTM) and umbilical cord matrix (UCM), in tendon management, both in vitro and in vivo. The abstract focuses on assessing the biomaterials’ biomechanical properties, immunomodulatory effects, and preclinical outcomes in clinically relevant models to advance their potential in tendon repair.
Robert J. Hariri, M.D., Ph.D., Celularity Chairman, CEO and Founder, noted, “Tendon injuries, whether due to sports-related activities, overuse, or degenerative conditions, present significant challenges in both treatment and recovery. I am very excited about the growing opportunity and potential of our decellularized placental biomaterials in tendon management and healing. The global tendon market accounted for USD 2.3 billion in 2022 and is projected to achieve a market size of USD 4.8 billion by 2032, growing at a CAGR of 7.6% from 2023 to 2032. We are committed to to growing our regenerative biomaterials business through innovations like this which we believe will significantly contribute to revenue growth. I am confident Celularity’s placental technology can be an important therapeutic tool in the management of these debilitating injuries.”
Anna Gosiewska, Ph.D., Vice President of Research and Development for Degenerative Diseases, who leads Celularity’s development of advanced biomaterials and cell technologies, added, “Decellularized placental biomaterials offer a rich source of native, developmentally early extracellular matrix that we believe is beneficial for tissue repair and regeneration. By carefully processing and engineering these biomaterials, Celularity is developing advanced therapeutic solutions tailored specifically for tendon injuries. We believe our innovative technologies utilizing decellularized placental biomaterials represent a novel approach in the field of tendon injury management and may offer patients and healthcare providers new hope for improved outcomes and enhanced quality of life.”
The study results described in the abstract provide insights into an in vivo evaluation of Celularity’s decellularized placental biomaterials in two clinically relevant models. The results demonstrate more advanced healing in the UCM treated group and complete incorporation of UCM into the tendon within three months post-implantation. These data indicate that human placental decellularized biomaterials may represent a promising matrix suitable for tendon management and healing.
Through strategic collaborations with leading academic institutions and healthcare partners, Celularity is working to advance treatments for musculoskeletal disorders and beyond.
The Celularity abstract authors include Dr. Anna Gosiewska, Desiree Long, Dr. Raja Sivalenka, Joseph Gleason, Dr. Adrian Kilcoyne, Dr. Robert J Hariri, and Dr. Steve A Brigido. The study was performed in close collaboration with scientific leaders from some of the nation’s top research organizations.
About Celularity Celularity Inc. (NASDAQ: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes that, by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
For more information, visit www.celularity.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include, without limitation, the application of connective tissue matrix (CTM) and umbilical cord matrix (UCM) in tendon management, the effects of decellularized placental biomaterials in tissue repair and regeneration, the impact of Celularity’s innovative technologies in the field of tendon repair and patient outcomes, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity’s liquidity situation; the volatility in Celularity’s stock price; inherent risks in biotechnological development, including with respect to the development of novel biomaterial therapies; along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Celularity Investor Contact: Carlos Ramirez, SVP, Investor Relations Celularity Inc. [email protected]
